Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.

Abstract

OBJECTIVE:

To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term.

METHODS:

We examined 131 patients with RA who had been treated with abatacept for more than 1 year. All patients underwent high-resolution computed tomographic (HRCT) scanning of the chest before administration of abatacept, and we examined deterioration of ILD over a follow-up period after administration of abatacept was initiated.

RESULTS:

Eleven patients (8.4%) showed deterioration of ILD over a mean follow-up period of 47.8 months. The factors related to ILD deterioration were use of methotrexate (MTX) [odds ratio 12.75, 95% confidence interval (CI) 1.09-148.77], and change in Krebs von-den Lungen-6 (odds ratio 1.00, 95% CI 1.00-1.01), according to multivariate logistic regression analysis.

CONCLUSION:

MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD.

• Authors: Takeshi Mochizuki, Katsunori Ikari, Koichiro Yano, Motoaki Sato, Ken Okazaki
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 29 Issue 3 Pg. 413-417 (May 2019) ISSN: 1439-7609 [Electronic] England
• PMID: 29798700 (Publication Type: Journal Article)

Chemical References

• Antirheumatic Agents
• Abatacept
• Methotrexate

Topics

• Abatacept (adverse effects, therapeutic use)
• Aged
• Antirheumatic Agents (adverse effects, therapeutic use)
• Arthritis, Rheumatoid (complications, drug therapy)
• Female
• Humans
• Lung Diseases, Interstitial (diagnostic imaging, epidemiology, etiology)
• Male
• Methotrexate (adverse effects, therapeutic use)
• Middle Aged
• Tomography, X-Ray Computed